Recurrent tuberculosis and its risk factors: Adequately treated patients are still at high risk

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 8, 2007, Pages 828-837

  Comstock, G W ^a   Golub, J E ^a,c   Panjabi, Rajesh ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pulmonary tuberculosis; Recurrence; Risk factors

Indexed keywords

CD4 ANTIGEN; DNA; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

CD4 LYMPHOCYTE COUNT; DISEASE SEVERITY; DRUG SUBSTITUTION; EPIDEMIC; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LUNG CAVITATION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK FACTOR; SPUTUM CULTURE; SYSTEMATIC REVIEW; TISSUE DISTRIBUTION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

HIV INFECTIONS; HUMANS; INCIDENCE; RECURRENCE; RISK FACTORS; TUBERCULOSIS;

EID: 34547751289     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. World Health Organization. WHO report 2006. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2006.362. Geneva, Switzerland: WHO, 2006.
2. Chaisson R E, Clermont H C, Holt E A, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154: 1034-1038.
3. Sonnenberg P, Murray J, Glynn J R, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693.
4. Murray J, Sonnenburg P, Shearer S C, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir CritCare Med 1999; 159: 733-740.
5. Johnson J, Kagal A, Bharadwaj R. Factors associated with drug resistance in pulmonary tuberculosis. Indian J Chest Dis Allied Sci 2003; 45: 105-109.
6. Garcia-Garcia M, Ponce-de León A, Jimenez-Corona M E, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in Southern Mexico. Arch Intern Med 2000; 160: 630-636.
7. Fujiwara P I, Cook S V, Rutherford C M, et al. A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med 1997; 157: 531-536.
8. Selassie A W, Pozsik C, Wilson D, Ferguson P L. Why pulmonary tuberculosis recurs: a population-based epidemiological study. Ann Epidemiol 2005; 15: 519-525.
9. Thomas A, Gopi P G, Santha T, et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis 2005; 9: 556-561.
10. Cowie R L, Langton M E, Becklake M R. Pulmonary tuberculosis in South African gold miners. Am Rev Respir Dis 1989; 139: 1086-1089.
11. Lambert M-L, Hasker E, Van Deun A, et al. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 2003; 3: 282-287.
12. Driver C R, Munsiff S S, Li J, Kundamal N, Osahan S S. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 2001; 33: 1762-1769.
13. Perriens J H, St Louis M E, Mukadi Y B, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-784.
14. Sterling T R, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13: 1899-1904.
15. Nettles R E, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38: 731-736.
16. Aber V R, Nunn A J. Factors affecting relapse following short-course chemotherapy. Bulletin Int Union 1978; 53 (4): 260-264.
17. Tuberculosis Research Centre, Chennai. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 1997; 1: 509-517.
18. Slutkin G, Schecter G F, Hopewell P C. The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco. Am Rev Respir Dis 1988; 138: 1622-1624.
19. Cao J P, Zhang L Y, Zhu J O, et al. Two-year follow-up of directly-observed intermittent regimens for smear-positive pulmonary tuberculosis in China. Int J Tuberc Lung Dis 1998; 2: 360-364.
20. Tam C M, Chan S L, Kam K M, Goodall R L, Mitchison D A. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 2002; 6: 3-10.
21. Kennedy N, Berger L, Curram J, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22: 827-833.
22. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991; 143: 707-712.
23. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Am Rev Respir Dis 1991; 143: 700-706.
24. Combs D L, O'Brien R J, Geiter L J. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 1990; 112: 397-406.
25. Singapore Tuberculosis Service/British Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1988; 137: 1147-1150.
26. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339-1342.
27. Snider D E, Graczyk J, Bek E, Rogowski J. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984; 130: 1091-1094.
28. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 1982; 126: 460-462.
29. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 579-585.
30. Mallory K F, Churchyard G J, Kleinschmidt I, De Cock K M, Corbett E L. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Dis 2000; 4: 455-462.
31. Connolly C, Reid A, Davies G, Sturm W, McAdam K P W J, Wilkinson D. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 1999; 13: 1543-1547.
32. Pulido F, Pena J-M, Rubio R, et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997; 157: 227-232.
33. Gilks C F, Godfrey-Faussett P, Batchelor B I, et al. Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya. AIDS 1997; 11: 911-918.
34. Malkin J E, Prazuck T, Simonnet F, et al. Tuberculosis and human immunodeficiency virus infection in west Burkina Faso: clinical presentation and clinical evolution. Int J Tuberc Lung Dis 1997; 1: 68-74.
35. Okwera A, Johnson J L, Luzze H, et al. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. Int J Tuberc Lung Dis 2006; 10: 39-44.
36. The Tuberculosis Trials Consortium, Atlanta. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002; 360: 528-534.
37. Johnson J L, Okwera A, Vjecha M J, et al. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 1997; 1: 446-453.
38. Fitzgerald D W, Desvarieux M, Severe P, Joseph P, Johnson W D Jr, Pape J W. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356: 1470-1474.
39. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-1847.
40. Gonzalez-Montaner L J, Natal S, Yongchaiyud P, et al. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Rifabutin Study Group. Tubercle Lung Dis 1994; 75: 341-347.
41. el-Sadr W M, Perlman D C, Matts J P, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998; 26: 1148-1158.
42. East African/British Medical Research Councils (1st study). Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1: 1079-1085.
43. Lawn S D, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-2116.
44. Wood R, Maartens G, Lombard C J. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23: 75-80.
45. van Rie A, Warren R, Richardson M, et al. Exogenous re-infection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179.
46. Fitzpatrick L K, Okwera A, Mugerwa R. An investigation of suspected exogenous re-infection in tuberculosis in Kampala, Uganda. Int J Tuberc Lung Dis 2002; 6: 550-552.
47. Bandera A, Gori A, Catozzi L, et al. Molecular epidemiology study of exogenous re-infection in an areas with a low incidence of tuberculosis. J Clin Microbiol 2001; 39: 2213-2218.
48. Jasmer R M, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004; 170: 1360-1366.
49. Chiang C-Y, Riley L W. Exogenous re-infection in tuberculosis. Lancet Infect Dis 2005; 5: 629-636.
50. Oyama T. Factors influencing relapse in pulmonary tuberculosis: a statistical analysis of 1259 patients followed from eleven months to six years after discharge. Am Rev Tuberc 1955; 72: 613-632
51. Tripathy S P. Relapse in tuberculosis. Indian J Tuberc 1981; 28: 45-57.
52. Corbett E L, Churchyard G J, Clayton T, et al. Risk factors for pulmonary mycobacterial disease in South African gold miners: a case-control study. Am J Respir Crit Care Med 1999; 159: 94-99.
53. Den Boon S, Bateman E D, Enarson D A, et al. Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung disease. Int J Tuberc Lung Dis 2005; 9: 1088-1096.
54. Wilkinson D, Bechan S, Connolly C, et al. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? Int J Tuberc Lung Dis 1998; 2: 52-55.
55. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis 1991; 143: 262-267.
56. World Health Organization. WHO report 2003. Treatment of tuberculosis: guidelines for national programmes, 3rd ed. WHO/CDS/TB/2003.313. Geneva, Switzerland: WHO, 2003.
57. Chang K C, Leung C C, Yew W W, et al. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 1153-1158.